Form 4: Kronos Bio CFO Deborah Knobelman Reports Acquisition of Shares and Stock Options
SEC Form 4 Filing
Deborah Knobelman, CFO of Kronos Bio, Inc., reports acquiring 164,260 shares of common stock and 246,390 employee stock options on June 3, 2024.
Summary
- On June 3, 2024, Deborah Knobelman, the Chief Financial Officer of Kronos Bio, Inc., acquired 164,260 shares of common stock.
- She also acquired 246,390 employee stock options with an exercise price of $0.745.
- 25% of the stock options will vest on June 3, 2025, with the remaining shares vesting in 36 equal monthly installments.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a standard disclosure of insider transactions. The acquisition of shares and options by the CFO could be interpreted as a slightly positive signal.
Positives
- The acquisition of shares and stock options by the CFO could be seen as a positive sign, indicating confidence in the company's future.
Industry Context
This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company executives.
Stakeholder Impact
- The acquisition of shares by the CFO could potentially increase investor confidence.
Key Dates
| Date | Description |
|---|---|
| 06/03/2024 | Date of transaction: Acquisition of common stock and employee stock options. |
| 06/03/2025 | 25% of the employee stock options vest. |
| 06/02/2034 | Expiration date of the employee stock options. |
| 06/04/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.